Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Becton Dickinson and Co    BDX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Becton Dickinson's 1st-Quarter Earnings Surge; Raises Year-View

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/05/2013 | 12:50pm CEST
   By Saabira Chaudhuri 
 

Becton Dickinson & Co.'s (>> Becton, Dickinson and Co.) fiscal first-quarter earnings more than doubled as the medical device maker recorded revenue growth across all its segments, while margins also widened.

For the current year, Becton raised the bottom end of its revenue guidance, now expecting foreign currency neutral revenue growth starting at 4% versus its prior view starting at 3.5%. It now expects per-share earnings from continuing operations between $5.69 and $5.72, up from its prior view of earnings between $5.58 and $5.64.

The maker of products like surgical blades and test kits last spring struck a deal to sell the bulk of its lab-products business to Corning Inc. (>> Corning Incorporated) for $730 million in cash. Analysts who follow the company noted the sale stripped Becton Dickinson of a cash cow yet also gave it the freedom to focus on businesses with higher growth potential.

Ahead of the company's earnings announcement, analysts at Mizuho Securities downgraded Becton's ratings, noting that the company's life science research business--which makes up about 15% of sales--has been a drag on results for the past year, adding that they see no significant catalysts for the business in the near-term, as the academic market continues to be sluggish.

Still, Chief Executive Vincent A. Forlenza on Tuesday said the company is "starting to see notable results," adding that Becton is "growing revenues across our three segments, driving margin expansion and delivering a higher quality of earnings."

For the quarter ended Dec. 31, Becton Dickinson reported a profit of $625.4 million, or $3.13 a share, compared with $263 million, or $1.21 a share, a year earlier. Per-share earnings from continuing operations were $1.35 versus $1.14.

Revenue increased 3.7% to $1.9 billion. Analysts polled by Thomson Reuters most recently forecast earnings of $1.24 a share on revenue of $1.86 billion.

Gross margin widened to 52.9% from 50.8%.

Becton Dickinson's sales grew 3% in the U.S. and 4.3% internationally. The company's medical unit, its largest by revenue, reported sales rose 3.5%. The diagnostics business posted revenue growth 5%, while bioscience revenue was up 1.7%.

Shares closed Monday at $85.16 and were inactive premarket. The stock has risen 11% in the past three months.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Becton, Dickinson and Co., Corning Incorporated
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BECTON DICKINSON AND CO
10:58a BECTON DICKINSON AND : BD Licenses Novel Molecular Indexing Technology to Roche;..
04/27 Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale ..
04/27 BECTON DICKINSON AND : BD Advances Efforts to Combat Antimicrobial Resistance wi..
04/26 BECTON DICKINSON AND : BD to Acquire Bard for $24 Billion
04/26 BECTON DICKINSON AND : BD Licenses Novel Molecular Indexing Technology to Roche
04/25 WEISSLAW LLP : The C. R. Bard, Inc. and Becton, Dickson and Company Merger May N..
04/25 C.R. BARD INVESTOR ALERT BY THE FORM : Kahn Swick & Foti, LLC Investigates Adequ..
04/25 BECTON DICKINSON AND CO : Blog Coverage Becton, Dickinson and C. R. Bard Set to ..
04/25 BECTON DICKINSON AND : Buys c.r. bard
04/25 BECTON DICKINSON AND : Snags Bard in $24B Merger
More news
Sector news : Medical Supplies
04/24DJWHAT'S NEWS : Business & Finance -- WSJ
04/24 Becton Dickinson to acquire Bard for $24 billion
04/23DJBECTON DICKINSON AND : to Acquire C.R. Bard for $24 Billion
04/19DJCardinal Swoops In, Strikes Deal -- WSJ
04/18DJCARDINAL HEALTH : $6.1 Billion Deal for Some Medtronic Operations Raises Debt Co..
More sector news : Medical Supplies
News from SeekingAlpha
04/27 My Dividend Growth Portfolio - Q1 2017 Summary
04/27 DIVIDEND STREAKS IN DANGER : 2016 Review And 2017 Preview
04/25 The Return Of Medtech Scale-Building?
04/25 Becton Dickinson (BDX) Acquires C.R. Bard (BCR) For $24B - Slideshow
04/25 The Real Reason For Market Rally - Cramer's Mad Money (4/24/17)
Advertisement
Financials ($)
Sales 2017 12 039 M
EBIT 2017 2 778 M
Net income 2017 1 648 M
Debt 2017 8 868 M
Yield 2017 1,60%
P/E ratio 2017 22,16
P/E ratio 2018 20,35
EV / Sales 2017 3,96x
EV / Sales 2018 3,60x
Capitalization 38 851 M
More Financials
Chart BECTON DICKINSON AND CO
Duration : Period :
Becton Dickinson and Co Technical Analysis Chart | BDX | US0758871091 | 4-Traders
Full-screen chart
Technical analysis trends BECTON DICKINSON ...
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 192 $
Spread / Average Target 5,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Vincent A. Forlenza Chairman, President & Chief Executive Officer
Christopher R. Reidy EVP, Chief Financial & Administrative Officer
Ellen R. Strahlman Chief Medical Officer, EVP-Research & Development
Bertram L. Scott Independent Director
Gary A. Mecklenburg Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BECTON DICKINSON AND C..10.27%38 851
TELEFLEX INCORPORATED28.12%9 283
SHANDONG WEIGAO GROUP ..10.10%3 261
HARTALEGA HOLDINGS BER..--.--%1 870
TOP GLOVE CORPORATION ..--.--%1 323
HOGY MEDICAL CO., LTD.-0.69%1 041
More Results